ArticleNature medicine2020
Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas.
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 87 citations in OpenAlex.
- Trial
- The Metabolomic Signature of Stressful Life Events.medRxiv : the preprint server for health sciences · 2026Article
- New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026Review
- Proteomic profiling of Alzheimer's disease and Vascular dementia reveals unique underlying signatures.medRxiv : the preprint server for health sciences · 2025Article
- Interplay between age, APOE Ɛ4 and the metabolome in plasma and brain in Alzheimer's disease.Translational psychiatry · 2025Article
- A multi-omics-empowered framework for precision diagnosis and treatment of lysosomal diseases.Journal of pharmaceutical analysis · 2025Review
- BioWalk-MDA: a novel approach for large-scale predicting metabolite-drug associations based on multi layered biomedical knowledge graphs.Briefings in bioinformatics · 2025Article
- Dual inhibition of FAS and HAS2/3 by 4-MU in Realgar-Coptis chinensis unveils a metabolic checkpoint for liver cancer therapy.Natural products and bioprospecting · 2025Article
- Gut microbes and their metabolites in relation to the classic tumor suppressor gene P53: a novel narrative.NPJ biofilms and microbiomes · 2025Review
- Repurposing the memory-promoting meclofenoxate hydrochloride as a treatment for Parkinson's disease through integrative multi-omics analysis.NPJ Parkinson's disease · 2025Article
- Epigenome-wide association study of incident type 2 diabetes in Black and White participants from the Atherosclerosis Risk in Communities Study.Diabetologia · 2025Article
- DHCLHAM: microbe-drug interaction prediction based on dual-hypergraph contrastive learning framework with hierarchical attention mechanism.Frontiers in microbiology · 2025Article
- Linking the gut microbiome to host DNA methylation by a discovery and replication epigenome-wide association study.BMC genomics · 2024Article
- The metabolome-wide signature of major depressive disorder.Molecular psychiatry · 2024Article
- Interlaboratory comparison of standardised metabolomics and lipidomics analyses in human and rodent blood using the MxPbioRxiv : the preprint server for biology · 2024Article
- Western diets and chronic diseases.Nature medicine · 2024Review
- Identification of blood metabolites associated with risk of Alzheimer's disease by integrating genomics and metabolomics data.Molecular psychiatry · 2024Article
- Circulating metabolites modulated by diet are associated with depression.Molecular psychiatry · 2023Article
- Metabolomics signatures of depression: the role of symptom profiles.Translational psychiatry · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress in high-throughput metabolic profiling provides unprecedented opportunities to obtain insights into the effects of drugs on human metabolism. The Biobanking BioMolecular Research Infrastructure of the Netherlands has constructed an atlas of drug-metabolite associations for 87 commonly prescribed drugs and 150 clinically relevant plasma-based metabolites assessed by proton nuclear magnetic resonance. The atlas includes a meta-analysis of ten cohorts (18,873 persons) and uncovers 1,071 drug-metabolite associations after evaluation of confounders including co-treatment. We show that the effect estimates of statins on metabolites from the cross-sectional study are comparable to those from intervention and genetic observational studies. Further data integration links proton pump inhibitors to circulating metabolites, liver function, hepatic steatosis and the gut microbiome. Our atlas provides a tool for targeted experimental pharmaceutical research and clinical trials to improve drug efficacy, safety and repurposing. We provide a web-based resource for visualization of the atlas (http://bbmri.researchlumc.nl/atlas/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.